<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02891083</url>
  </required_header>
  <id_info>
    <org_study_id>2016shchest</org_study_id>
    <nct_id>NCT02891083</nct_id>
  </id_info>
  <brief_title>Adjuvant Therapies or Surgery Alone for High Risk pN0 Esophageal Cancer</brief_title>
  <official_title>Multi-center Prospective Randomized Controlled Clinical Trial of Postoperative Adjuvant Chemotherapy, Adjuvant Radiotherapy, or Surgery Alone for High-risk Histological Node Negative Patients With Thoracic Esophageal Squamous Cell Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Chest Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Tianjin Medical University Cancer Institute and Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sichuan Cancer Hospital and Research Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hunan Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Fujian Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Fudan University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Qingdao University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Fujian Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Wuhan TongJi Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Shanghai Chest Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Histological Node Negative thoracic esophageal squamous cell carcinoma（pN0 ESCC） after
      radical resection still carries the risk of recurrence after complete surgical resection,
      especially in some high-risk patients. There are still lack of knowledge on postoperative
      treatment indication and methods for pN0 ESCC.Our previous study has shown that risk of
      recurrence is associated with the location and cell differentiation of primary tumor, as well
      as the presence of lymphovascular invasion. This project is designed to study the efficacy of
      adjuvant therapies for at patients with pN0 ESCC and above mentioned risk factors of
      recurrence after radical surgery. We aim to compare the differences among adjuvant
      chemotherapy, adjuvant radiotherapy, and surgery alone for pN0 ESCC by prospective randomized
      controlled trial. There has been no similar studies in esophageal cancer previously reported
      with similar design. The results of this study is expected to have a high clinical relevance.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study is designed to be a prospective randomized controlled trial, aiming to compare the
      impact of adjuvant chemotherapy with Paclitaxel and Cisplatin, adjuvant radiotherapy with
      IMRT of 50Gy, and surgery alone on the disease free survival (DFS) of patients with high-risk
      pN0 thoracic esophageal squamous cell carcinoma. Pathological staging is to be based on the
      7th UICC edition, after radical resection and systemic lymph node dissection,for accurate
      staging.Patients with pT1b-T4a disease, proved to be pN0 upon pathological examination, meet
      at least one of the risk factors in the inclusion criteria, and without any exclusion
      criteria are to be randomized into one of the three study arms.Definition of high-risk
      factors for recurrence include: (1)Tumor location: in the middle or upper third thoracic
      esophagus; (2) Presence of LVI or submucosal metastasis; (3) Cell differentiation: poorly
      differentiated or undifferentiated.

      Primary endpoint:

      To observe and compare Disease-Free Survivals (DFS) among the three study arms.

      Secondary endpoint:

      To observe and compare Overall Survivals (OS) among the three study arms, and to compare
      adverse events between adjuvant chemotherapy and adjuvant radiation groups.

      Additional instructions:

      No.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2016</start_date>
  <completion_date type="Anticipated">January 2021</completion_date>
  <primary_completion_date type="Anticipated">January 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Disease free survival</measure>
    <time_frame>3 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>side effect of adjuvant therapy</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">486</enrollment>
  <condition>Esophageal Neoplasms</condition>
  <arm_group>
    <arm_group_label>Adjuvant chemotherapy group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Surgery followed by adjuvant chemotherapy,with Paclitaxel and Cisplatin.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Adjuvant radiotherapy group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Surgery followed by 50Gy adjuvant radiotherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Surgery alone</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Adjuvant chemotherapy (Paclitaxel and Cisplatin)</intervention_name>
    <description>Adjuvant chemotherapy group: three cycles: (Paclitaxel: 175mg/m2 ivgtt, 3h, d1 4week × 3 and cisplatin: 75mg/m2 ivgtt, d1 4 week × 3)</description>
    <arm_group_label>Adjuvant chemotherapy group</arm_group_label>
    <other_name>Paclitaxel and Cisplatin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Adjuvant radiotherapy</intervention_name>
    <description>Target: the upper mediastinum and bilateral supraclavicular region (Upper bound: thyrocricoid, lower bound: carina of 3cm)
Dose: 50Gy
Technology: strong tone
Segmentation: conventional segmentation 2Gy/d</description>
    <arm_group_label>Adjuvant radiotherapy group</arm_group_label>
    <other_name>cobalt-60</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Control group (Surgery alone)</intervention_name>
    <arm_group_label>Control group</arm_group_label>
    <other_name>Surgery alone</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patient: No pretreatment before surgery.Informed consent signed after screening;

          2. Surgery: Complete (R0) resection of tumor, with thoraco- abdominal two-field or
             cervico-thoraco-abdominal three-field lymph node dissection through transthoracic
             esophagectomy. At least 12 stations and 12 lymph nodes should be harvested, including
             bilateral recurrent laryngeal nerve nodes. Both open thoracotomy and minimally
             invasive thoracoscopic/laparoscopic approaches are allowed and histopathological
             examination confirmed the diagnosis of the patients with at least cleaning more or
             equal to 12 stations and 12 lymph nodes;

          3. Histology: Thoracic esophageal squamous cell carcinoma, with no nodal involvement
             (pN0) after pathological examination;

          4. Staging: Tumor T stage T1b-T4a according to the 7th UICC esophageal cancer staging
             system;

          5. Definition of high risk for recurrence: meet at least one of the three below.

             A: Primary tumor located in middle or upper third of thoracic esophagus

             B: Presence of lymphovascular invasion (LVI) or submucosal metastasis

             C: Cell differentiation:Low grade or undifferentiated

          6. Performance status: ECOG score 0-2;

          7. Cardiac function:NYHA classification 1-2. Normal electrocardiogram;

          8. Renal function: Normal serum creatinine level (SCr = 120mol/L) and creatinine
             clearance rate (CCr = 60 ml/min);

          9. Hepatic function: Serum aspartate aminotransferase (AST) and alanine aminotransferase
             (ALT) level less than or equal to 2.0 times the upper limit of normal (ULN). Serum
             alkaline phosphatase (ALP) level less than or equal to four times the upper limit of
             normal value. Serum total bilirubin level less than or equal to 1.5 times the upper
             limit of the normal value;

         10. Hematopoietic function: White blood cell count (WBC) equal to or more than 4000 /
             μL,neutrophils (ANC) absolute count is more than or equal to 1500 / μ L, platelet
             count more than or equal to 100000/ μ L, hemoglobin equal to or more than 10.0 g / dl.

        Exclusion Criteria:

          1. Surgery through Left thoracic or transhiatal approach, whereby complete
             lymphadenectomy is not achieved;

          2. Patients experienced severe postoperative complication and thus, are unable to
             tolerate any adjuvant therapy;

          3. Patients who have concommitant other malignant tumor;

          4. Patients with abnormal coagulation function, with bleeding tendencies (such as active
             peptic ulcer) or are currently receiving thrombolysis or anticoagulation therapies;

          5. Severe cardiac comorbidities, including congestive heart failure,uncontrolled cardiac
             arrhythmia, unstable angina pectoris, myocardial infarction within six months,severe
             heart valve disease, or intractable hypertension;

          6. Severe hepatic or renal insufficiency;

          7. Poor mental status or mental disorders, poor compliance.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wentao Fang, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shanghai Chest Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Wentao Fang, MD</last_name>
    <phone>+86-21-62821990</phone>
    <phone_ext>2901</phone_ext>
    <email>vwtfang12@shcheat.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Xufeng Guo, MD</last_name>
    <phone>+86-21-62821990</phone>
    <phone_ext>2608</phone_ext>
    <email>shandagxf@126.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Shanghai Chest Hospital</name>
      <address>
        <city>Shanghai</city>
        <zip>200030</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wentao Fang, MD</last_name>
      <phone>+86-21-62821990</phone>
      <phone_ext>2901</phone_ext>
      <email>vwtfang12@shchest.org</email>
    </contact>
    <contact_backup>
      <last_name>Xufeng Guo, MD</last_name>
      <phone>+86-21-62821900</phone>
      <phone_ext>2608</phone_ext>
      <email>shandagxf@126.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <results_reference>
    <citation>Guo XF, Mao T, Gu ZT, Ji CY, Fang WT, Chen WH. Clinical study on postoperative recurrence in patients with pN0 esophageal squamous cell carcinoma. J Cardiothorac Surg. 2014 Aug 28;9:150. doi: 10.1186/s13019-014-0150-4.</citation>
    <PMID>25164541</PMID>
  </results_reference>
  <results_reference>
    <citation>Shim YM, Kim HK, Kim K. Comparison of survival and recurrence pattern between two-field and three-field lymph node dissections for upper thoracic esophageal squamous cell carcinoma. J Thorac Oncol. 2010 May;5(5):707-12. doi: 10.1097/JTO.0b013e3181d3ccb2.</citation>
    <PMID>20421764</PMID>
  </results_reference>
  <results_reference>
    <citation>Ando N, Iizuka T, Ide H, Ishida K, Shinoda M, Nishimaki T, Takiyama W, Watanabe H, Isono K, Aoyama N, Makuuchi H, Tanaka O, Yamana H, Ikeuchi S, Kabuto T, Nagai K, Shimada Y, Kinjo Y, Fukuda H; Japan Clinical Oncology Group. Surgery plus chemotherapy compared with surgery alone for localized squamous cell carcinoma of the thoracic esophagus: a Japan Clinical Oncology Group Study--JCOG9204. J Clin Oncol. 2003 Dec 15;21(24):4592-6.</citation>
    <PMID>14673047</PMID>
  </results_reference>
  <results_reference>
    <citation>Tachimori Y, Nagai Y, Kanamori N, Hokamura N, Igaki H. Pattern of lymph node metastases of esophageal squamous cell carcinoma based on the anatomical lymphatic drainage system. Dis Esophagus. 2011 Jan;24(1):33-8. doi: 10.1111/j.1442-2050.2010.01086.x.</citation>
    <PMID>20626450</PMID>
  </results_reference>
  <results_reference>
    <citation>Wu SG, Dai MM, He ZY, Sun JY, Lin HX, Lin H, Li Q. Patterns of Regional Lymph Node Recurrence After Radical Surgery for Thoracic Esophageal Squamous Cell Carcinoma. Ann Thorac Surg. 2016 Feb;101(2):551-7. doi: 10.1016/j.athoracsur.2015.08.057. Epub 2015 Oct 31.</citation>
    <PMID>26530541</PMID>
  </results_reference>
  <verification_date>September 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 1, 2016</study_first_submitted>
  <study_first_submitted_qc>September 6, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 7, 2016</study_first_posted>
  <last_update_submitted>September 6, 2016</last_update_submitted>
  <last_update_submitted_qc>September 6, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 7, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shanghai Chest Hospital</investigator_affiliation>
    <investigator_full_name>Wentao Fang</investigator_full_name>
    <investigator_title>Chief Director,Clinical Center of Esophageal Diseases,Shanghai Jiao tong University</investigator_title>
  </responsible_party>
  <keyword>adjuvant chemotherapy</keyword>
  <keyword>adjuvant radiotherapy</keyword>
  <keyword>lymph node metastasis</keyword>
  <keyword>surgery</keyword>
  <keyword>squamous cell carcinoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Esophageal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

